For the first time, the G20 Leaders’ Declaration explicitly references the Lusaka Agenda  – a significant milestone for developing countries that have long called for a fairer global health architecture. This acknowledgement gives political weight to an agenda that places integrated health systems, universal health coverage, and national leadership at the center of global health […] Continue reading ->
In August 2025, Guyana’s President Irfaan Ali removed all taxes and customs duties on feminine hygiene products. Now, Guyana’s Ambassador to the UN in Geneva calls on other countries to follow suit.    In most developing countries male condoms are distributed freely. Free access to condoms is a globally recognized harm reduction strategy in public health.  […] Continue reading ->
Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO).  Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading ->
The United States government is moving rapidly to secure Memorandums of Understanding (MOU) with African countries that offer limited health aid for five years in exchange for 25 years’ access to countries’ data about “pathogens with epidemic potential”. Some commentators have described the terms of the bilateral MOUs as “extractive” as they fail to offer […] Continue reading ->
A $300 million investment in projects integrating health into climate action has been announced at the UN Climate Conference in Bélem, Brazil by a coalition of “Climate and Health Funders Coalition” which includes over 35 of the world’s leading philanthropies and foundations, including Rockefeller, Gates and Wellcome.  This announcement was made at the high-level opening […] Continue reading ->
The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates.  A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading ->